Lyell Immunopharma Inc
LYEL
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Lyell Immunopharma is a clinical-stage biotechnology company developing T-cell therapies for cancer. Its core research and development pipeline, including its lead CAR T-cell candidates, is predicated on animal testing. The company's preclinical studies, as standard for the biopharmaceutical industry, utilize animal models to evaluate the safety and efficacy of its therapeutic candidates. This reliance on animal testing is a foundational and non-negotiable component of its drug development process to meet regulatory requirements for human clinical trials. While specific details on the scale or nature of these tests are not publicly disclosed in its financial filings, the business model of bringing novel cell therapies to market inherently involves the commercial exploitation of animals in research.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.